Sera Prognostics (NASDAQ:SERA) Stock Price Up 0.4%

Sera Prognostics, Inc. (NASDAQ:SERA)’s share price was up 0.4% on Friday . The company traded as high as $7.35 and last traded at $7.25. Approximately 49,759 shares were traded during trading, a decline of 75% from the average daily volume of 196,666 shares. The stock had previously closed at $7.22.

Sera Prognostics Price Performance

The firm has a market capitalization of $241.93 million, a price-to-earnings ratio of -6.78 and a beta of 1.03. The firm has a 50 day moving average price of $7.12 and a 200-day moving average price of $8.33.

Sera Prognostics (NASDAQ:SERA) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02). Sera Prognostics had a negative net margin of 11,843.79% and a negative return on equity of 46.71%. The company had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.08 million. During the same period in the prior year, the business earned ($0.34) EPS. Equities research analysts predict that Sera Prognostics, Inc. will post -0.95 earnings per share for the current year.

Insider Buying and Selling

In other Sera Prognostics news, CFO Austin Aerts sold 5,415 shares of the stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $8.11, for a total value of $43,915.65. Following the sale, the chief financial officer now directly owns 310,481 shares of the company’s stock, valued at approximately $2,518,000.91. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, insider John J. Boniface sold 5,022 shares of the firm’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $7.42, for a total transaction of $37,263.24. Following the sale, the insider now owns 129,847 shares of the company’s stock, valued at approximately $963,464.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Austin Aerts sold 5,415 shares of the company’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $8.11, for a total value of $43,915.65. Following the completion of the transaction, the chief financial officer now directly owns 310,481 shares of the company’s stock, valued at $2,518,000.91. The disclosure for this sale can be found here. Insiders sold 56,492 shares of company stock worth $441,445 over the last 90 days. 15.80% of the stock is owned by insiders.

Institutional Trading of Sera Prognostics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Sanders Morris Harris LLC acquired a new position in shares of Sera Prognostics in the 1st quarter valued at $174,000. StepStone Group LP acquired a new position in Sera Prognostics in the fourth quarter valued at $61,000. The Manufacturers Life Insurance Company acquired a new position in Sera Prognostics in the second quarter valued at $68,000. Renaissance Technologies LLC purchased a new position in shares of Sera Prognostics during the second quarter worth about $162,000. Finally, American Century Companies Inc. increased its position in shares of Sera Prognostics by 12.7% during the second quarter. American Century Companies Inc. now owns 25,682 shares of the company’s stock worth $152,000 after purchasing an additional 2,891 shares in the last quarter. Institutional investors and hedge funds own 54.64% of the company’s stock.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.